Wei Guo Su
Chief Executive Officer bij HUTCHMED (CHINA) LIMITED
Vermogen: 16 M $ op 31-03-2024
Actieve functies van Wei Guo Su
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
HUTCHMED (CHINA) LIMITED | Director/Board Member | 27-03-2017 | - |
Chief Executive Officer | 04-03-2022 | - | |
Chief Tech/Sci/R&D Officer | 01-01-2012 | - | |
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Chief Tech/Sci/R&D Officer | 24-03-2010 | - |
Loopbaan van Wei Guo Su
Eerdere bekende functies van Wei Guo Su
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
PFIZER, INC. | Corporate Officer/Principal | - | - |
Opleiding van Wei Guo Su
Harvard University | Doctorate Degree |
Fudan University | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 3 |
China | 3 |
Hongkong | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
PFIZER, INC. | Health Technology |
HUTCHMED (CHINA) LIMITED | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Hutchison MediPharma Ltd.
Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China. | Health Technology |
- Beurs
- Insiders
- Wei Guo Su
- Ervaring